Workspace 04 · Clinical Trials & Evidence Generation

Trial AI matters only when it strengthens participant protection and reliable evidence.

This workspace maps AI across protocol design, feasibility, recruitment, monitoring, safety review, data management, analysis, reporting, and real-world evidence where traceable records matter more than generic acceleration.

Focus: trial evidence · GCP · recordsRisk: untraceable influenceBridge: protocol · data · decision record
Clinical Trials traceProtocolSiteDataSafetyAnalysisRecordAIsystemsource to workflow to evidence to review
AI in Healthcare/Clinical Trials & Evidence Generation
/ workspace

Clinical Trials & Evidence Generation workspace.

9 chapter surfaces

This workspace maps AI across protocol design, feasibility, recruitment, monitoring, safety review, data management, analysis, reporting, and real-world evidence where traceable records matter more than generic acceleration.

/ map

Source-to-use operating map.

how this workspace reads AI
Operating map
InventoryList the AI systems, actors, records, and workflows in scope.
RiskClassify impact, uncertainty, affected users, and plausible harms.
EvidenceConnect claims to validation, source data, limitations, and monitoring.
ReviewKeep owners, decisions, revisions, and open questions visible.
Chapter 01

Overview

The overview defines the boundary of Clinical Trials & Evidence Generation: what belongs in scope, what remains outside the claim, and what evidence has to travel with any public or operational interpretation.

source-backedRead →
Chapter 02

Use Cases

Use cases in Clinical Trials are sorted by the decision they affect and the evidence they require, not by the attractiveness of the tool demonstration.

source-backedRead →
Chapter 03

Data Substrate

The data substrate for Clinical Trials determines what the model can know, what it misses, what it amplifies, and what remains reviewable later.

source-backedRead →
Chapter 04

Model Lifecycle

The lifecycle view treats AI in Clinical Trials as a managed capability: design, validation, deployment, monitoring, update, rollback, and retirement.

source-backedRead →
Chapter 05

Validation & Evidence

Validation evidence for Clinical Trials connects technical performance to the real workflow, population, user, and decision context.

source-backedRead →
Chapter 06

Governance & Risk

Governance and risk for Clinical Trials define who can approve use, what harms are plausible, which controls apply, and when use is paused or escalated.

source-backedRead →
Chapter 07

Operations & Adoption

Operations and adoption in Clinical Trials focus on whether teams can use the system consistently, challenge it safely, and learn from real use.

source-backedRead →
Chapter 08

Market & Actors

The market and actor layer for Clinical Trials maps who builds, sells, deploys, uses, monitors, audits, and regulates the capability.

source-backedRead →
Chapter 09

Updates & Assets

The updates and assets layer keeps Clinical Trials alive through weekly signals, source maps, checklists, explainers, and revision notes.

source-backedRead →
/ sources

Source anchors and claim boundary.

official first

These anchors support the source layer for this workspace. iFeed interpretation stays separate from source facts and does not replace legal, regulatory, clinical, or product-specific advice.